News

Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB ...
The American Journal of Managed Care16h
Breaking Ground in Breast Cancer: A New Standard in TNBC, a New Way to Target ESR1
Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...